This inventor holds 33 USPTO granted patents and 1 EPO patent, primarily in Therapeutic Agents. Top assignees: Merck Sharp + Dohme Corp., Merck Sharpe & Dohme Corp., Dohme Ltd.. Active years: 1994-2009.
Location History:
- Royston, GB (1994)
- Puckridge, GB (1996)
- Harlow, GB (1995 - 2001)
- Puckeridge, GB (1996 - 2003)
- Buntingford, GB (2002 - 2009)
Company Filing History:
28 out of 2,405 
2 out of 36 
1 out of 1 
Years Active: 1994-2009
Areas of Expertise:
Title: Neil Roy Curtis: Innovating in Neuropharmacology
Neil Roy Curtis, a prolific inventor based in Puckeridge, GB, has made significant contributions to the field of neuropharmacology, holding an impressive total of 33 patents. His innovations focus primarily on the development of compounds aimed at addressing critical neurological conditions, showcasing his dedication to improving patient outcomes.
Latest Patents
Among his latest patents, a notable invention includes compounds that serve as potent and selective 5-HT antagonists. These compounds are particularly useful in treating a variety of adverse conditions affecting the central nervous system (CNS). Another significant patent focuses on substituted carbocyclic sulphonamide derivatives, which act as selective 5-HT receptor antagonists. These derivatives are designed to be effective in treating various neurological issues, including depression and sleep disorders, thereby demonstrating his commitment to addressing pressing health challenges.
Career Highlights
Throughout his career, Neil has been associated with leading pharmaceutical companies, including Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp. His roles within these organizations have allowed him to collaborate with some of the industry's foremost researchers and develop groundbreaking therapies that have the potential to change lives.
Collaborations
Neil has worked alongside notable colleagues such as Janusz Jozef Kulagowski and Raymond Baker. These collaborations have further enhanced his innovative capabilities, blending diverse expertise to tackle complex neurological disorders through effective pharmacological solutions.
Conclusion
In summary, Neil Roy Curtis stands out as a significant figure in the realm of innovation within neuropharmacology. His numerous patents and collaborations underscore his commitment to advancing treatments for neurological conditions, making him a key contributor to the field. As he continues to develop new compounds, the impact of his work is likely to resonate in the medical community for years to come.